½ÃÀ庸°í¼­
»óǰÄÚµå
1584734

¼¼°èÀÇ ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå : À¯Çüº°, ¾àÁ¦ Ŭ·¡½ºº°, À¯Åë ä³Îº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Allergy Relieving Eye Drops Market by Type, Drug Class, Distribution Channel, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 184 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀº 2023³â¿¡ 4¾ï 5,016¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 4¾ï 8,165¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 7.39%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 7¾ï 4,159¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾àÀº ²É°¡·ç, ¸ÕÁö, ¹Ý·Áµ¿¹° ºñµë µîÀÇ ¾Ë·¹¸£±âÀ¸·Î ÀÎÇÑ °¡·Á¿òÁõ, ÃæÇ÷, ´«¹° µîÀÇ Áõ»óÀ» ¿ÏÈ­Çϱâ À§ÇØ °í¾ÈµÈ Ư¼ö Á¡¾È¾àÀÔ´Ï´Ù. °èÀý¼º ¾Ë·¹¸£±â Áõ°¡¿Í ȯ°æ ¿À¿°ÀÇ ½É°¢È­·Î ÀÎÇØ ´«ÀÇ ºÒÄè°¨ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ±× Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¡¾ÈÁ¦´Â ÆÛ½º³ÎÄɾîºÎÅÍ ÀÓ»ó ±Ç°í¿¡ À̸£±â±îÁö ´Ù¾çÇÑ Àå¸é¿¡¼­ Àû¿ëµÇ¸ç Áï°¢ÀûÀÎ ¿ÏÈ­¿Í Àå±â ¿ÏÈ­¿¡ ¸ðµÎ µµ¿òÀÌ µË´Ï´Ù. ÃÖÁ¾ ¿ëµµÀÇ ¹üÀ§´Â ½ÃÆÇ¾à°ú ó¹æÀüÀ» ¸ðµÎ Æ÷ÇÔÇÏ¸ç °æµµ¿¡¼­ ½ÉÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀÇ Áõ»ó ¿ÏÈ­¸¦ Ãß±¸ÇÏ´Â ±¤¹üÀ§ÇÑ ¼ÒºñÀÚ¸¦ ¼ö¿ëÇÕ´Ï´Ù. ½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é ¼ºÀåÀº ÁÖ·Î ´« °Ç°­¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í, ¼¼°è ¾Ë·¹¸£±âÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϰí, ´«°ú °ü·ÃµÈ ¹®Á¦¸¦ °ÞÀ» ¼ö ÀÖ´Â ³ëÀÎÃþÀÇ È®´ë¿¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹æºÎÁ¦°¡¾ø´Â ¿É¼Ç°ú Ç×È÷½ºÅ¸¹Î°ú Ç× ¿°Áõ È¿°ú¸¦ ¸ðµÎ Á¦°øÇÏ´Â µà¾ó ¾×¼Ç Á¡¾ÈÁ¦¿Í °°Àº Á¦ÇüÀÇ Çõ½ÅÀº ÁÖ¸ñÇÒ¸¸ÇÑ ÀáÀçÀû ±âȸÀÔ´Ï´Ù. ±â¾÷Àº ½ÃÀå Á¡À¯À²À» ¾ò±â À§ÇØ Á¦Ç°ÀÇ È¿À²¼ºÀ» ³ôÀ̰í Á¦Ç°À» ´Ù¾çÈ­Çϱâ À§ÇØ R&D¿¡ ÅõÀÚÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù. ±×·¯³ª ºÎÀÛ¿ëÀÇ °¡´É¼º, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, Ȧ¸®½ºÆ½, ºñ¾à¸®ÇÐÀû Ä¡·á¹ý¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÃëÇâ µîÀÇ Á¦¾àÀÌ ¾öû³­ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±âÁ¸ Á¦Ç°ÀÇ Æ÷È­ »óÅÂ¿Í ¼ÒºñÀÚÀÇ ½Å·Ú¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Á¦Ç° ȸ¼ö »ç·Ê·Î ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÇ °¡´É¼ºÀÌ ÀÖ´Â ºÐ¾ß·Î´Â °í±Þ Áø´Ü ÅøÀ» »ç¿ëÇÏ¿© °³º° ¾Ë·¹¸£±â ÇÁ·ÎÆÄÀÏ¿¡ ´ëÀÀÇÏ´Â °³º°È­ Á¡¾È¾àÀÇ °³¹ßÀ̳ª ÅëÇÕ ¼Ö·ç¼ÇÀ¸·Î ´«ÀÇ °Ç°­À» °¨½Ã, °ü¸®Çϱâ À§ÇÑ µðÁöÅÐ Çコ?Ç÷§ÆûÀÇ È°¿ë µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀÌ¸ç ¼ÒºñÀÚÀÇ Àǽİú ±ÔÁ¦ »óȲ¿¡ Å©°Ô ¿µÇâÀ» ¹Þ±â ¶§¹®¿¡ ±â¾÷Àº ¹ÎøÇÏ°Ô ÇൿÇϰí ÄÄÇöóÀÌ¾ð½º¿Í °í°´ Âü¿©¸¦ °­Á¶ÇÏ°í ¼ºÀåÀ» °¡¼ÓÇØ¾ßÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 4¾ï 5,016¸¸ ´Þ·¯
¿¹Ãø³â(2024) 4¾ï 8,165¸¸ ´Þ·¯
¿¹Ãø³â(2030) 7¾ï 4,159¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 7.39%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¼¼·ÃµÇ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°è Àα¸ÀÇ ´« ¾Ë·¹¸£±â ¹× ´« ÁúȯÀÇ À¯º´·ü
    • Àû½ÃÀÇ ¾È°ú °ËÁø°ú ¾È°ú À§»ý¿¡ °üÇÑ Á¤ºÎÀÇ ´ëó
    • ¿Â¶óÀÎ ¾à±¹¿¡ ÀÇÇÑ ¾Ë·¹¸£±â¿ë ¾È¾àÀÇ Æø³ÐÀº ÀÌ¿ë °¡´É¼º
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¡¾È ±â¼úÀÇ ¾î·Á¿ò
  • ½ÃÀå ±âȸ
    • »õ·Î¿î Á¡¾È¾àÀÇ ¿¬±¸°³¹ßÀÇ °è¼Ó
    • »õ·Î¿î ¾Ë·¹¸£±â ¿ÏÈ­Á¦ÀÇ ¼Ò°³
  • ½ÃÀåÀÇ °úÁ¦
    • ¾Ë·¹¸£±â Á¡¾È¾àÀÇ ¸®ÄÝ ±ÞÁõ

Porter's Five Forces : ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ ¹× °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ© ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®È­Çϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀÇ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ Áú¹®¿¡ ÀÀ´äÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°è Àα¸¿¡¼­ ´«ÀÇ ¾Ë·¹¸£±â¿Í Áúº´ÀÇ À¯º´·ü
      • ÀûÀýÇÑ ½Ã±â ¾È°ú °ËÁø°ú ´« °Ç°­¿¡ °üÇÑ Á¤ºÎÀÇ ´ëó
      • ¿Â¶óÀÎ ¾à±¹¿¡¼­ ¾Ë·¹¸£±â¿ë ¾È¾àÀÌ Æø³Ð°Ô ÀÔ¼ö °¡´É
    • ¾ïÁ¦¿äÀÎ
      • Á¡¾È ±â¼ú¿¡ ¼ö¹ÝÇÏ´Â °ï¶õ
    • ±âȸ
      • »õ·Î¿î Á¡¾È¾àÀÇ À¯È¿ ¼ººÐÀÇ µµÀÔÀ» ÇâÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß
      • »õ·Î¿î ¾Ë·¹¸£±â ¿ÏÈ­Á¦ ±â¼úÀÇ ¼Ò°³
    • °úÁ¦
      • ¾Ë·¹¸£±â¿ë Á¡¾È¾àÀÇ ¸®ÄÝÀÌ ±ÞÁõ
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå : À¯Çüº°

  • ¾ÆÅäÇǼº °¢°á¸·¿°
  • °Å´ë À¯µÎ °á¸·¿°
  • °èÀý¼º ¹× ¿¬Áß ¾Ë·¹¸£±â¼º °á¸·¿°
  • Ãá°è īŻ

Á¦7Àå ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

  • Ç×È÷½ºÅ¸¹ÎÁ¦
  • ÃæÇ÷ Á¦°ÅÁ¦
  • ºñ¸¸ ¼¼Æ÷ ¾ÈÁ¤Á¦
  • ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦
  • Ç÷°ü ¼öÃàÁ¦

Á¦8Àå ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå : À¯Åë ä³Îº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ÆÇ¸Å
  • ¼Ò¸Å

Á¦9Àå ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ȨÄɾî
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾Ë·¹¸£±â ¿ÏÈ­ Á¡¾È¾à ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • AbbVie Inc.
  • Akorn, Inc.
  • Alcon Inc.
  • Amneal Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch & Lomb Incorporated
  • Bausch Health Companies Inc.
  • CVS Health
  • Dr. Reddy's Laboratories Ltd.
  • Geri-Care Pharmaceuticals Corp.
  • Honeywell International Inc.
  • Johnson & Johnson services, Inc.
  • Lupin Pharmaceutical, Inc.
  • Mankind Pharma Ltd.
  • Mylan NV
  • Nicox SA
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • OCuSOFT Inc.
  • Pfizer, Inc.
  • Prestige Consumer Healthcare Inc.
  • ROHTO Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Similasan Corporation
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt
BJH 24.11.14

The Allergy Relieving Eye Drops Market was valued at USD 450.16 million in 2023, expected to reach USD 481.65 million in 2024, and is projected to grow at a CAGR of 7.39%, to USD 741.59 million by 2030.

Allergy-relieving eye drops are specialized ophthalmic solutions designed to alleviate symptoms like itching, redness, and watering caused by allergens such as pollen, dust, and pet dander. Their necessity is underscored by the increasing prevalence of seasonal allergies and escalating rates of pollution, which exacerbate ocular discomfort. These drops find applications in diverse settings, from personal care to clinical recommendations, serving both immediate and long-term relief purposes. The end-use scope encompasses both over-the-counter and prescription segments, catering to a broad range of consumers seeking symptomatic relief from mild to severe allergic reactions. Market insights reveal that growth is primarily influenced by heightened awareness of ocular health, increasing incidences of allergies globally, and the expanding geriatric demographic more prone to eye-related issues. Moreover, innovations in formulation, such as preservative-free options and dual-action drops that offer both antihistamine and anti-inflammatory benefits, are notable potential opportunities. Companies are advised to invest in research and development to enhance product efficacy and diversify offerings to capture market share. However, limitations such as possible side effects, stringent regulatory requirements, and consumer preference for holistic and non-pharmacological remedies present formidable challenges. Moreover, market growth could be hindered by the saturation of existing products and instances of product recalls impacting consumer trust. Potential areas for innovation include the development of personalized drops that cater to individual allergen profiles using advanced diagnostic tools, and leveraging digital health platforms for monitoring and managing eye health with integrated solutions. The market is dynamic, heavily influenced by consumer awareness and regulatory landscapes, indicating that businesses must be agile, focusing on compliance and customer engagement to drive growth.

KEY MARKET STATISTICS
Base Year [2023] USD 450.16 million
Estimated Year [2024] USD 481.65 million
Forecast Year [2030] USD 741.59 million
CAGR (%) 7.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Allergy Relieving Eye Drops Market

The Allergy Relieving Eye Drops Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of eye allergies and disorders among the population worldwide
    • Government initiatives regarding timely eye checkups and ophthalmic health
    • Wide availability of allergy eye drops through online pharmacies
  • Market Restraints
    • Difficulties associated with eye drop techniques
  • Market Opportunities
    • Ongoing R&D for introducing new eye drop actives
    • Introduction of new allergy relieving drug techniques
  • Market Challenges
    • Surging incidence of allergy eye drop recalls

Porter's Five Forces: A Strategic Tool for Navigating the Allergy Relieving Eye Drops Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Allergy Relieving Eye Drops Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Allergy Relieving Eye Drops Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Allergy Relieving Eye Drops Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Allergy Relieving Eye Drops Market

A detailed market share analysis in the Allergy Relieving Eye Drops Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Allergy Relieving Eye Drops Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Allergy Relieving Eye Drops Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Allergy Relieving Eye Drops Market

A strategic analysis of the Allergy Relieving Eye Drops Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Allergy Relieving Eye Drops Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Akorn, Inc., Alcon Inc., Amneal Pharmaceuticals, Inc., Astellas Pharma Inc., Bausch & Lomb Incorporated, Bausch Health Companies Inc., CVS Health, Dr. Reddy's Laboratories Ltd., Geri-Care Pharmaceuticals Corp., Honeywell International Inc., Johnson & Johnson services, Inc., Lupin Pharmaceutical, Inc., Mankind Pharma Ltd., Mylan N.V., Nicox SA, Novartis AG, Ocular Therapeutix, Inc., OCuSOFT Inc., Pfizer, Inc., Prestige Consumer Healthcare Inc., ROHTO Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Similasan Corporation, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt.

Market Segmentation & Coverage

This research report categorizes the Allergy Relieving Eye Drops Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Atopic Keratoconjunctivitis, Giant Papillary Conjunctivitis, Seasonal & Perennial Allergic Conjunctivitis, and Vernal Keratoconjunctivitis.
  • Based on Drug Class, market is studied across Antihistamines, Decongestant, Mast cell stabilizers, Non-Steroidal Anti-Inflammatory Drugs, and Vasoconstrictors.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Sales, and Retail.
  • Based on End-User, market is studied across Homecare and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of eye allergies and disorders among the population worldwide
      • 5.1.1.2. Government initiatives regarding timely eye checkups and ophthalmic health
      • 5.1.1.3. Wide availability of allergy eye drops through online pharmacies
    • 5.1.2. Restraints
      • 5.1.2.1. Difficulties associated with eye drop techniques
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D for introducing new eye drop actives
      • 5.1.3.2. Introduction of new allergy relieving drug techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Surging incidence of allergy eye drop recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Allergy Relieving Eye Drops Market, by Type

  • 6.1. Introduction
  • 6.2. Atopic Keratoconjunctivitis
  • 6.3. Giant Papillary Conjunctivitis
  • 6.4. Seasonal & Perennial Allergic Conjunctivitis
  • 6.5. Vernal Keratoconjunctivitis

7. Allergy Relieving Eye Drops Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antihistamines
  • 7.3. Decongestant
  • 7.4. Mast cell stabilizers
  • 7.5. Non-Steroidal Anti-Inflammatory Drugs
  • 7.6. Vasoconstrictors

8. Allergy Relieving Eye Drops Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Sales
  • 8.4. Retail

9. Allergy Relieving Eye Drops Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals & Clinics

10. Americas Allergy Relieving Eye Drops Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Allergy Relieving Eye Drops Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Allergy Relieving Eye Drops Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Akorn, Inc.
  • 3. Alcon Inc.
  • 4. Amneal Pharmaceuticals, Inc.
  • 5. Astellas Pharma Inc.
  • 6. Bausch & Lomb Incorporated
  • 7. Bausch Health Companies Inc.
  • 8. CVS Health
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Geri-Care Pharmaceuticals Corp.
  • 11. Honeywell International Inc.
  • 12. Johnson & Johnson services, Inc.
  • 13. Lupin Pharmaceutical, Inc.
  • 14. Mankind Pharma Ltd.
  • 15. Mylan N.V.
  • 16. Nicox SA
  • 17. Novartis AG
  • 18. Ocular Therapeutix, Inc.
  • 19. OCuSOFT Inc.
  • 20. Pfizer, Inc.
  • 21. Prestige Consumer Healthcare Inc.
  • 22. ROHTO Pharmaceutical Co., Ltd.
  • 23. Santen Pharmaceutical Co., Ltd.
  • 24. Similasan Corporation
  • 25. Sun Pharmaceutical Industries Limited
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Wockhardt
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦